CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024.
CASI製藥公司（納斯達克股票代碼：CASI），一家註冊在開曼群島的生物藥企，專注於開發和商業化創新治療方案和藥品產品，宣佈任命丹尼爾·朗醫學博士爲公司首席財務官兼高級副總裁，任期自2024年7月8日起生效。
Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.
朗博士作爲一名醫學科學家、投資人和生物科技行業高管擁有超過30年的從業經驗。他是加州舊金山大學的心臟科醫生，之後在法拉隆資本擔任20年的投資經理和RS投資價值集團的首席投資官。最近，他擔任埃森諾斯NKt細胞治療部門的總裁，並領導NKt細胞平台的臨床開發。
譯文內容由第三人軟體翻譯。